Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?

Osteoporosis International

Volumn 23, Issue 8, 2012, Pages 2159-2167

  Kwok, T ^a   Leung, J ^b   Zhang, Y F ^c   Bauer, D ^d   Ensrud, K E ^e   Barrett Connor, E ^f   Leung, P C ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NANTONG UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Bone density

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANDROGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOCORTICOID; LOOP DIURETIC AGENT; NITRATE; STATIN; STEROID; THIAZIDE DIURETIC AGENT; VITAMIN D;

AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; FRAGILITY FRACTURE; HUMAN; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; WESTERN HEMISPHERE;

ABSORPTIOMETRY, PHOTON; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BONE DENSITY; BONE RESORPTION; FEMUR; FEMUR NECK; HIP JOINT; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864883420     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1831-7     Document Type: Article

References (37)

1. So WY, Ma RC, Ozaki R et al (2006) Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-interaction with ACE insertion/deletion polymorphism. Kidney Int 69 (8):1438-1443
2. Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861-869
3. Hatton R, Stimpel M, Chambers TJ (1997) Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 152(1):5-10
4. Hiruma Y, Inoue A, Hirose S et al (1997) Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun 230(1):176-178
5. Lynn H, Kwok T, Wong SY et al (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584-588
6. Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24(3):581-589
7. Pérez-Castrillón JL, Silva J, Justo I et al (2003) Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 16(6):453-459
8. Orwoll E, Black JB, Barrett-Connor E et al (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26(5):569-585
9. Blank JB, Cawthon PM, Carrion-Petersen ML et al (2005) Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials 26(5):557-568
10. Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46:153-162
11. Woo J, Lynn H, Wong SY, Hong A, Tang YN, Lau WY, Lau E, Orwoll E, Kwok TC (2006) Correlates for a low ankle-brachial index in elderly Chinese. Atherosclerosis 186(2):360-366
12. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1-S266
13. D'Agostino RB Jr. (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281
14. Bolland MJ, Ames RW, Horne AM et al (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18(4):479-486
15. Uzzan B, Cohen R, Nicolas P et al (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40 (6):1581-1587
16. Rejnmark L, Vestergaard P, Heickendorff L et al (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21(1):163-170
17. Jamal SA, Cummings SR, Hawker GA (2004) Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res 19(9):1512-1517
18. Pasco JA, Henry MJ, Sanders KM et al (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19(1):19-24
19. Wong SYS, Kwok T, Lynn H, Griffith JF, Leung J, Tang YYN, Leung PC (2005) Bone mineral density and the risk of peripheral vascular disease in men and women: results from the Mr. and Ms Os, Hong Kong. Osteoporos Int 16:1933-1938
20. Ishani A, Paudel M, Taylor BC, Barrett-Connor E, Jamal S, Canales M, Steffes M, Fink HA, Orwoll E, Cummings SR, Ensrud KE, Osteoporotic Fractures in Men (MrOS) Study Group (2008) Renal function and rate of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Osteoporos Int 19(11):1549-1556
21. Inzerillo AM, Epstein S (2004) Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 5(3):261-268
22. Gerdhem P, Isaksson A, Akesson K et al (2005) Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 16(12):1506-1512
23. Murphy CE, Rodgers PT (2007) Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 41(12):2014-2018
24. Masunari N, Fujiwara S, Nakata Yet al (2008) Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci 57(1):17-25
25. Shimizu H, Nakagami H, Osako MK et al (2008) Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22 (7):2465-2475
26. Shimizu H, Nakagami H, Osako MK, Nakagami F, Kunugiza Y, Tomita T, Yoshikawa H, Rakugi H, Ogihara T, Morishita R (2009) Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens Res 32 (9):786-790
27. Woo J, Leung SS, Ho SC et al (1998) Dietary intake and practices in the Hong Kong Chinese population. J Epidemiol Community Health 52(10):631-637
28. Chan JC, Cheung CK, Cockram CS et al (1994) Atrial natriuretic peptide and renin-angiotensin-aldosterone system in non-insulindependent diabetes mellitus. J Hum Hypertens 8(6):451-456
29. Azizi M, Chatellier G, Guyene TT et al (1995) Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92(4):825-834
30. Koshida H, Takeda R, Miyamori I (1998) Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Hypertens Res 21(4):279-282
31. Kwok T, Ohlsson C, Vandenput L, Tang N, Zhang YF, Tomlinson B, Leung PC (2010) ACE inhibitor use was associated with lower serum dehydroepiandrosterone concentrations in older men. Clin Chim Acta 411(15-16):1122-1125
32. Izu Y, Mizoguchi F, Kawamata A et al (2008) Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem 284 (8):4857-4864
33. Asaba Y, Ito M, Fumoto T et al (2008) Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 24(2):241-250
34. Agata J, Ura N, Yoshida H et al (2006) Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 29(11):865-874
35. Bandow K, Nishikawa Y, Ohnishi T, Kakimoto K, Soejima K, Iwabuchi S, Kuroe K, Matsuguchi T (2007) Low-intensity pulsed ultrasound (LIPUS) induces RANKL, MCP-1, and MIP-1beta expression in osteoblasts through the angiotensin II type 1 receptor. J Cell Physiol 211(2):392-398
36. Zhang Y, Yeung B, Qin L, Kwok T (2009) The effect of angiotensin II type I receptor blocker (ARB) on bone loss in orchidectomized male hypertensive and normotensive rats. 36th European symposium on calcified tissues. Vienna, May 2009, p. 512
37. Musini VM, Fortin PM, Bassett K, Wright JM (2008) Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev (4):CD007066